A review of GPR65, a protein tied to acid around tumors
Original title: GPR65 in cancer: expression heterogeneity, invasion and metastasis, the tumor immune microenvironment, and translational implications.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This looks across many earlier studies rather than running a new one.
This is a summary of past research, and the one drug is only in early tests in people.
The short version
Scientists are studying a protein that may help tumors survive and hide from the immune system.
What was studied. This is a review paper. It gathers what past studies say about a protein called GPR65 in cancer. The studies covered several cancers, including glioma: A tumor that starts in the glial cells, the support cells of the brain and spinal cord. Gliomas are graded 1 to 4 by how fast they tend to grow. See the glossary, a kind of brain tumor.
What they found. The area around a tumor is often acidic. The review says GPR65 senses that acid and may help tumor cells live in it. It may also make immune cells work less well against cancer. Its role was not the same in every cancer type.
What this means, and what it doesn't
What it could mean: One pill that blocks GPR65, called PTT-4256, is being tested in people. Safety is still a big question. At the 300-mg dose, one person had multiple organ failure and died. Doctors said the drug probably caused it, and that dose is no longer being tested. Nothing here is a treatment a patient can get today.
What it doesn't mean: This is not a new result and it is not a cure. It is a summary of where the science stands. The one drug is in the earliest kind of human testing. The right dose, the full safety picture, and whether it actually fights cancer are all still unknown. This does not change anyone's care right now.
Source: PubMed, August 18, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.